Zastaprazan

A pharmaceutical drug used as a proton pump inhibitor

Zastaprazan is a pharmaceutical compound that functions as a proton pump inhibitor (PPI). It is primarily used in the treatment of conditions related to excessive stomach acid production, such as gastroesophageal reflux disease (GERD) and peptic ulcer disease.

Mechanism of Action

Zastaprazan works by inhibiting the H+/K+ ATPase enzyme system, commonly known as the gastric proton pump, located in the parietal cells of the stomach lining. This inhibition prevents the final step in the production of gastric acid, thereby reducing acid secretion. By decreasing stomach acidity, Zastaprazan helps in alleviating symptoms associated with acid-related disorders and promotes healing of the gastric mucosa.

Pharmacokinetics

Zastaprazan is administered orally and is absorbed in the small intestine. It is a prodrug that is activated in the acidic environment of the parietal cells. The drug is metabolized in the liver, primarily by the cytochrome P450 enzyme system, and is excreted through the kidneys.

Clinical Uses

Zastaprazan is indicated for the treatment of:

• Gastroesophageal reflux disease (GERD)
• Peptic ulcer disease
• Zollinger-Ellison syndrome
• Erosive esophagitis

Side Effects

Common side effects of Zastaprazan include headache, nausea, diarrhea, abdominal pain, and dizziness. Long-term use of proton pump inhibitors, including Zastaprazan, may be associated with an increased risk of osteoporosis-related fractures, Clostridium difficile infection, and hypomagnesemia.

Drug Interactions

Zastaprazan may interact with other medications that are metabolized by the cytochrome P450 system. It can also affect the absorption of drugs that require an acidic environment for optimal absorption, such as ketoconazole and iron supplements.

Development and Approval

Zastaprazan is developed by pharmaceutical companies focusing on novel treatments for acid-related disorders. It is subject to regulatory approval processes in various countries, where its safety and efficacy are evaluated through clinical trials.

Related pages

• Proton pump inhibitor
• Gastroesophageal reflux disease
• Peptic ulcer disease
• H+/K+ ATPase

Chemical structure of Zastaprazan